Patents Assigned to Chiesi Farmaceutici S.p.A.
  • Publication number: 20240092790
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
  • Publication number: 20240092791
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
  • Publication number: 20240092792
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME
  • Publication number: 20240082223
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 14, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Roberta MAZZUCATO, Christine EDWARDS, Adele Elisa PASQUA
  • Publication number: 20240025880
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 25, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Sara GUARIENTO, Charles BAKER-GLENN, Hervé VAN DE POËL, Kim Louise HIRST
  • Publication number: 20240018122
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 18, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
  • Publication number: 20240002371
    Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 4, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
  • Publication number: 20230416233
    Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: December 28, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
  • Patent number: 11844860
    Abstract: A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa as active ingredients and one or more excipients. Once dispersed in an aqueous medium, melevodopa is completely dissolved, and carbidopa is present as nanoparticles.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: December 19, 2023
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Ricardo Inacio, Mark Saunders, Bhanvi Mehta, Kathrin Muehlhoelzl-Odoerfer, Isabel Sole Font, Grazia Caivano
  • Publication number: 20230364015
    Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.
    Type: Application
    Filed: July 17, 2023
    Publication date: November 16, 2023
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Daniela COCCONI, Rossella Musa
  • Patent number: 11813360
    Abstract: The present invention concerns carrier particles suitable for use in dry powder formulations for inhalation. The invention also relates to processes for their preparation by spray-congealing.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: November 14, 2023
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Tomaso Guidi, Amrit Paudel, Sarah Elizabeth Zellnitz, Joana Filipa Fernandes Teixeira Pinto
  • Publication number: 20230277451
    Abstract: The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of at least two inorganic acids, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.
    Type: Application
    Filed: October 8, 2021
    Publication date: September 7, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Enrico ZAMBELLI, Sauro BONELLI, Diego COPELLI, Massimiliano DAGLI ALBERI, Francesca USBERTI
  • Patent number: 11737989
    Abstract: Provided is a pharmaceutical composition comprising clevidipine in a sterile, ready to use, physically stable, aqueous dispersion of nanoparticles that stabilizes clevidipine against formation of impurities and is suitable for parenteral administration.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: August 29, 2023
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Rajeshwar Motheram, David C. Hanley, Sr., Akif Emre Tureli, Monika Kanter
  • Patent number: 11725007
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: August 15, 2023
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Gurdip Bhalay, Patrizia Tisselli
  • Patent number: 11723874
    Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 15, 2023
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Bernard Charles Sherman, Michael Spino
  • Publication number: 20230250093
    Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 10, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta ARMANI, Gabriele AMARI, Andrea RIZZI, Mafalda PAGANO, Luca RAVEGLIA, Claudia BEATO
  • Publication number: 20230227447
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
    Type: Application
    Filed: May 24, 2021
    Publication date: July 20, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Bartosz Pawel GUT
  • Publication number: 20230210880
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Application
    Filed: March 10, 2023
    Publication date: July 6, 2023
    Applicant: Chiesi Farmaceutici S. p. A.
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
  • Patent number: 11660409
    Abstract: An electronic module for an inhaler includes a printed circuit board and electronic components configured to detect at least a status and/or at least a working parameter of the inhaler when the electronic module is attached to the inhaler. A battery is permanently joined to the printed circuit board. A first terminal and a second terminal are electrically connectable one to the other through a main switch to close a circuit between the battery and the electronic components. In a rest configuration, the first and second terminals are electrically separated by the main switch. In a work configuration, the first terminal and the second terminal are electrically connected one to the other through the main switch.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: May 30, 2023
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alan Tweedie, Colin Mitchell, Scott Lewis, Andrew T. Heidt, Robert Rudolf
  • Publication number: 20230157951
    Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro BONELLI, Francesca USBERTI, Enrico ZAMBELLI